NRX-101 (D-Cycloserine + Lurasidone) Is Active against Drug-Resistant Urinary Pathogens In Vitro.

Michael T Sapko, Michael Manyak, Riccardo Panicucci, Jonathan C Javitt

Open access · goldAbstract read

In one paragraph

Article in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

–field-weighted citation impact, top 94% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

Mechanism-Based Polypharmacy as a Repurposing Strategy: The Case of D-Cycloserine and Lurasidone.Clinical and translational science · 2026
Review
AI-driven drug reposition for pathogens: a new paradigm in pandemic preparedness.Frontiers in chemistry · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Michael T SapkoNRx Pharmaceuticals, 1201 N Market St, Suite 111, Wilmington, DE 19801, USA.ORCID 0000-0002-8381-2367

Michael ManyakDepartment of Urology, George Washington University, 900 23rd Street NW, Washington, DC 20037, USA.ORCID 0000-0002-6251-7238

Riccardo PanicucciNRx Pharmaceuticals, 1201 N Market St, Suite 111, Wilmington, DE 19801, USA.

Jonathan C JavittNRx Pharmaceuticals, 1201 N Market St, Suite 111, Wilmington, DE 19801, USA.

Wilmington University · USGeorge Washington University · USJohns Hopkins University · US

Funding

NRx Pharmaceuticals N/A

6 · The paper itself

Abstract

D-Cycloserine (DCS) is a broad-spectrum antibiotic that is currently FDA-approved to treat tuberculosis (TB) disease and urinary tract infection (UTI). Despite numerous reports showing good clinical efficacy, DCS fell out of favor as a UTI treatment because of its propensity to cause side effects. NRX-101, a fixed-dose combination of DCS and lurasidone, has been awarded Qualified Infectious Disease Product and Fast Track Designation by the FDA. In this study, we tested NRX-101 against the urinary tract pathogens

Indexed as

antimicrobialscomplicated urinary tract infectionsD-cycloserinemultidrug resistanceNRX-101susceptibility testing

Identifiers

PMID38666984

DOI10.3390/antibiotics13040308

PMCPMC11047644

OpenAlexW4393279512

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.